Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · April 29, 2024

Tislelizumab Plus Platinum and Etoposide vs Placebo Plus Platinum and Etoposide as the First-Line Treatment for Patients With Extensive–Stage SCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
J Thorac Oncol 2024 Mar 07;[EPub Ahead of Print], Y Cheng, Y Fan, Y Zhao, D Huang, X Li, P Zhang, M Kang, N Yang, D Zhong, Z Wang, Y Yu, Y Zhang, J Zhao, T Qin, C Chen, S Leaw, W Zheng, Y Song

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading